WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Miao Girl Makes Intangible Cultural Heritage Alive in SW ChinaForeign Ministry gets new spokesmanChina's gigantic telescope provides nearly 900 observation hours to foreign researchersAcross China: Hainan's Ethnic Tea Grower Strives for Collective ProsperityNPC Deputy from Hunan Province Dedicated to Improving People's Livelihood at Grassroots LevelIndefatigable Team of Women Transform Barren Coastal Area of Hainan with Largescale TreeBranded 'English pigs', rumours of devilChinese paddlers shine at WTT Champions IncheonChina expects 17.5 mln rail passenger trips on first day of Qingming Festival holidayTeacher Guides Visually Impaired Kids on Career Path
1.8227s , 6499.6640625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Gazette news portal